Cantargia Ab

Fredax Ab

Alligator Bioscience Ab

Cecilia Ann-Christin Malmborg Hager

Kjell Sjöström

Karin Von Wachenfeldt

Marcus Järås

Thoas Fioretos

Agneta Svedberg

Helena Ågerstam

Anders Axelsson

Sven-Erik Strand

Amanda Thuy Tran

Björn Walse

Eva Maria Dahlén

Patrick Thomas Höjman

Marie Asa Ingegerd Karlsson

Mats Peter Anderson

Urpo Juhani Lamminmäki

Karin Elisabeth Barchan

Kjell SJÖSTRÖM

The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.

Antibody polypeptides and uses thereof

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody 'CAN04' to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.

Methods of treating IL1RAP associated cancers with anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

Methods of producing an IL-1 RAP antibodies

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.

Method of detection of IL1RAP on cells expressing the protein

Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

Anti-human interleukin-1 receptor accessory protein antibody and its use for treating cancer

The present disclosure provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1 RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody 'CAN04' to human IL1 RAP. The disclosure further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.

The invention provides an isolated polypeptide comprising a variant amino acid sequence of SEQ ID NO: 1, or a fusion or derivative of said polypeptide, or a fusion of a said derivative thereof, wherein the polypeptide, fusion or derivative retains a biological activity of wild type IL-IRa. In one embodiment, the isolated polypeptide, fusion or derivative is or comprises a polypeptide variant of amino acid sequence SEQ ID NO: 1 comprising or consisting of substitutions at one or more of the following amino acid mutations of SEQ ID NO: 1: Q29K, P38Y, P38R, L42W, D47N, E52R, H54R, E90Y, Q129L, Q129N, M136N, M136D and Q149K. Also provided are pharmaceutical compositions of the above polypeptide, fusion or derivative, as well as uses of the same for treating a disease or condition capable of being treated by an agent which inhibits the function of IL-1 receptors.

Mutants of interleukin-1 receptor antagonist

Growing community of inventors

Helsingborg, Sweden

Cecilia Ann-Christin Malmborg Hager